Dr. Avtar Dhillon reports
EMERALD HEALTH THERAPEUTICS ANNOUNCES EXECUTIVE CHAIRMAN AVTAR DHILLON APPOINTED AS PRESIDENT; CEO CHRIS WAGNER STEPS DOWN
Dr. Avtar Dhillon, executive chairman, has been appointed president of Emerald Health Therapeutics Inc. and Chris Wagner has stepped down as chief executive officer.
"Emerald's board of directors thanks Chris for his numerous contributions during this period of rapid growth and wishes him well in his future endeavours," said Jim Heppell, a director of Emerald. "Emerald has now laid the groundwork for very rapid future growth. As executive chairman, Dr. Dhillon has been intimately involved in setting the company's strategy and overseeing its operations. Under his experienced stewardship, we expect Emerald to rapidly advance its differentiated business plan."
Dr. Dhillon said: "Our plan is to build on the momentum of, and accelerate, our foray into the world cannabis arena and leverage our asset base to maximize our opportunities not only in Canada, but globally. Our goal is to be a pre-eminent player on the global stage, with science-backed innovative cannabinoid products. As such, we are finalizing our expansive relationship with the Factors Group, which, when complete, is expected to provide industrial-scale extraction, encapsulation, packaging and distribution capability. We intend to feed this processing capability with supply from our Pure Sunfarms joint venture, our Quebec facility and hemp to be obtained through our supply agreement."
Dr. Dhillon is a life sciences entrepreneur with more than 35 years of experience. He is chief executive officer of Emerald Health Sciences, a major shareholder of the company, and serves as a board member and chairman of several life science companies. He is also chairman of the Cannabis Canada Council. As a founder/co-founder of many life science companies, he has raised more than $1-billion in public and private financings. As president and chief executive officer of Inovio Pharmaceuticals Inc., Dr. Dhillon led a turnaround with multiple successful financings and licensing deals with Merck, Wyeth (now Pfizer) and Roche. Before joining Inovio, he was vice-president of MDS Capital Corp. (now Lumira Capital Corp.). Prior to his business career, Dr. Dhillon practised family medicine. He has a BSc (honours) in human physiology and an MD from the University of British Columbia.
Emerald would also like to announce the departure of Paul Dillman as executive vice-president of global sales and marketing of the company, effective as of Nov. 22, 2018. The board also thanks Mr. Dillman for his service.
About Emerald Health Therapeutics Inc.
Emerald Health Therapeutics is a Canadian licensed producer of cannabis. Its 50-per-cent-owned Pure Sunfarms joint venture in British Columbia is completing a sophisticated 1.1-million-square-foot greenhouse; its Agro-Biotech operation in Quebec is completing a 75,000-square-foot indoor facility. Commercial production is expanding in both facilities. It secured approximately 500 acres of hemp harvest in 2018 and has contracted for approximately 1,000 acres in 2019 to 2022 with the goal of extracting low-cost cannabidiol (CBD).
We seek Safe Harbor.
© 2019 Canjex Publishing Ltd. All rights reserved.